Building an OPAT program that is clinically safe and financially survivable

OPAT is one of the clearest value propositions in medicine: patients who would otherwise occupy an inpatient bed for weeks of intravenous antimicrobials complete therapy at home or in an outpatient setting, at lower total cost and with better experience. The clinical case has been settled for years. The payment case has not.

The coverage asymmetry at the centre of everything

The defining structural fact of US OPAT is that Medicare's coverage of home infusion antibiotics does not work the way clinicians expect. Published work in the infectious disease literature has documented the problem directly: Medicare does not reimburse home infusion of antimicrobials in the way commercial insurers generally do, and reimbursement has been available principally for days on which a health professional is present in the home.

The consequence is measurable. Research on OPAT delivery has reported that roughly a quarter of Medicare OPAT patients received antibiotics through home infusion, compared with around 60% of patients with other insurance — a difference driven by coverage design rather than by clinical suitability. Patients who cannot access home infusion are directed instead to skilled nursing facilities, infusion centres or extended inpatient stays.

Medicare's Home Infusion Therapy benefit and its payment structure have specific eligibility, drug-list and professional-visit requirements. Verify current rules against CMS guidance for the year in question before designing a program around them — this area has changed and continues to change.

What that means for your program design

Site of care is not a clinical preference in OPAT. It is a coverage determination that then constrains clinical options. A practical program has to plan for at least three pathways and know which patients fall into which:

• Home infusion — generally the lowest total cost and best patient experience, most accessible to commercially insured patients.
• Outpatient infusion centre or your own suite — the pathway that frequently absorbs patients who cannot access home infusion, with different payment mechanics for drug, administration and facility components.
• Skilled nursing facility — often the fallback for Medicare patients, with its own placement, coordination and quality considerations.

Design your intake process to determine the pathway early, because a therapy plan built before the coverage is understood will frequently have to be rebuilt.

The uncompensated coordination problem

The clinical literature on OPAT barriers is consistent: programs report substantial challenges around institutional support, reimbursement, and communication between stakeholders. A multi-centre US survey of OPAT management identified lack of leadership awareness, difficulty managing patients with substance use disorder, and timely access to laboratory results among the most commonly reported challenges.

Underneath each of those sits the same economic issue. OPAT requires work that is real, skilled, time-consuming and largely invisible to the billing system:

• Insurance verification and prior authorisation for both drug and site of care.
• Vascular access arrangement and complication management.
• Weekly laboratory monitoring, review and dose adjustment.
• Coordination with home infusion pharmacies, nursing agencies and facilities.
• Adverse event and line complication response, often out of hours.
• Readmission avoidance — the value that most benefits the hospital and least reaches the ID practice.

If this work is not either billed, contracted or explicitly staffed, it is being subsidised by the practice. Most struggling OPAT programs are not clinically deficient; they are financially unstructured.

Structuring the program so it survives

1. Decide who owns the coordination, and fund the role

An OPAT program without a dedicated coordinator — nurse or pharmacist — distributes the work across people who have other jobs, which is why it degrades under volume. Cost the role explicitly and identify what pays for it: contracted hospital support, infusion margin, avoided readmission arrangements, or clinical revenue.

2. Make the hospital relationship a contract, not a courtesy

OPAT delivers most of its financial value to the institution that avoids the inpatient days. If your program is doing that work, that value is a legitimate basis for a service agreement. Practices that never raise it are, in effect, donating the savings.

3. Define the monitoring protocol and hold to it

Standardised laboratory schedules, defined escalation criteria and a weekly review with documented decisions serve two purposes: they are the clinical safety backbone, and they are the documentation that supports the cognitive billing the program does generate.

4. Handle the hard populations deliberately

Patients with substance use disorder are a documented operational challenge in OPAT and are frequently excluded from home pathways by policy rather than by individual assessment. Whatever your program decides, decide it explicitly, with a written pathway, rather than case by case under time pressure.

Measuring whether it works

Track completion rate, unplanned readmission during therapy, line complication rate, and time from referral to first dose — alongside the financial measures: margin per course by site of care and by payer class, and coordination hours per course. Programs that measure only the clinical side never learn why they are losing money; programs that measure only the financial side lose the argument for institutional support.